The Lancet Oncology· Andrew Oar, Andrew Kneebone, Katrin M Sjoquist, David Espinoza, Mark Lee, Hien Le, Leily Gholamrezaei, Julie Chu, James Lynam, Girish Mallesara, Dominique Lee, Dinesh Vignarajah, Iain Ward, Jaswinder Samra, Andrew Barbour, Angela Whitehead, Susan Brooks, Anna Nicholson, Tim Wei Wang, Weng Ng, Fathalla Ali, Derrick Siu, Juanita Lopez Gaitan, Olivia Cook, Alisha Moore, Martinus B Oostendorp, Sonia Yip, John Shakeshaft, David Pryor, Nam Nguyen, David Goldstein, Australasian Gastro-Intestinal Trials Group (AGITG)·· 7 hours agoScore65
[Articles] Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group
In brief
The open-label, phase 2, multicentre MASTERPLAN randomised trial by the Australasian Gastro-Intestinal Trials Group (AGITG) showed that perioperative chemotherapy plus SBRT significantly reduced locoregional recurrence in high-risk, localised PDAC. Compared with perioperative chemotherapy alone, adding SBRT did not significantly increase toxicity; the authors say the strategy warrants investigation in larger studies.
Source: The Lancet Oncology · thelancet.com